Sinovac Biotech, Ltd
SVA
SVA was delisted on the 22nd of February, 2019.
26 hedge funds and large institutions have $421M invested in Sinovac Biotech, Ltd in 2024 Q1 according to their latest regulatory filings, with 18 funds opening new positions, 1 increasing their positions, 1 reducing their positions, and 0 closing their positions.
225% more funds holding
Funds holding: 8 → 26 (+18)
50% more funds holding in top 10
Funds holding in top 10: 2 → 3 (+1)
22% more capital invested
Capital invested by funds: $345M → $421M (+$75.5M)
0% more repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 1
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VC
Vivo Capital
Palo Alto,
California
|
+$76.3M |
| 2 |
State Street
Boston,
Massachusetts
|
+$1.04M |
| 3 |
Renaissance Technologies
New York
|
+$849K |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
+$179K |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$106K |
Top Sellers
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
O
1
OrbiMed
New York
| $340M | – | – | – |
|
|
VC
2
Vivo Capital
Palo Alto,
California
| $76.3M | +$76.3M | +11,800,000 | New |
|
|
NAH
3
Neumann Advisory (HK)
Central,
Hong Kong
| $2.04M | – | – | – |
|
|
4
State Street
Boston,
Massachusetts
| $1.04M | +$1.04M | +160,875 | New |
|
|
5
Renaissance Technologies
New York
| $849K | +$849K | +1,312,520 | New |
|
|
6
Geode Capital Management
Boston,
Massachusetts
| $179K | +$179K | +27,717 | New |
|
|
7
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| $106K | +$106K | +16,430 | New |
|
8
Wells Fargo
San Francisco,
California
| $82.5K | +$82.5K | +12,750 | New |
|
9
Morgan Stanley
New York
| $44.8K | +$44.8K | +6,924 | New |
|
10
JP Morgan Chase
New York
| $19.4K | +$19.4K | +3,000 | New |
|
11
UBS Group
Zurich,
Switzerland
| $13.6K | +$13.6K | +2,095 | New |
|
12
Group One Trading
Chicago,
Illinois
| $2.67K | +$2.67K | +412 | New |
|
|
TFA
13
Transamerica Financial Advisors
St. Petersburg,
Florida
| $1K | – | – | – |
|
|
HI
14
Horizon Investments
Charlotte,
North Carolina
| $336 | – | – | – |
|
SVA Hedge Fund Activity: Q1 2024 in Review
26 of the 6,942 institutional investors tracked by Wall St. Rank reported a position in Sinovac Biotech, Ltd (SVA) for Q1 2024, worth a combined $421M — up 22% from $345M a quarter earlier.
Buyers outnumbered sellers: 18 funds opened new SVA positions and 0 closed out — a net gain of 18 holders — while 1 added to existing stakes and 1 trimmed.
The largest buyer was Vivo Capital, opening a new position worth an estimated $76.3M.
- 26 institutional investors held Sinovac Biotech, Ltd (SVA) as of Q1 2024, up from 8 in Q4 2023.
- Funds reported $421M of Sinovac Biotech, Ltd stock for Q1 2024, up 22% quarter-over-quarter.
- 18 funds opened new Sinovac Biotech, Ltd positions in Q1 2024 and 0 closed out, a net change of +18 holders.
- The largest Sinovac Biotech, Ltd buyer in Q1 2024 was Vivo Capital, an estimated $76.3M added.
Based on aggregated 13F filings for Q1 2024.